Cypress Capital Management (Wyoming)’s Accelerate Diagnostics AXDX Stock Holding History

Cypress Capital Management (Wyoming)’s Portfolio AXDX Stock Details AXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-11	Closed	-$3K	–	197
2019 Q2	$3K	Hold	11	–	–	﹤0.01%	229
2019 Q1	$2K	Hold	11	–	–	﹤0.01%	242
2018 Q4	$1K	Hold	11	–	–	﹤0.01%	315
2018 Q3	$3K	Hold	11	–	–	﹤0.01%	317
2018 Q2	$2K	Sell	11 -10	-48%	-$2.24K	﹤0.01%	314
2018 Q1	$5K	Hold	21	–	–	0.01%	276
2017 Q4	$6K	Hold	21	–	–	0.01%	270
2017 Q3	$5K	Hold	21	–	–	0.01%	239
2017 Q2	$5.77K	Hold	21	–	–	0.01%	225
2017 Q1	$5.11K	Hold	21	–	–	0.01%	231
2016 Q4	$4.41K	Hold	21	–	–	﹤0.01%	229
2016 Q3	$5.75K	Hold	21	–	–	0.01%	195
2016 Q2	$3.04K	Sell	21 -35	-63%	-$4.69K	﹤0.01%	204
2016 Q1	$8.09K	Hold	56	–	–	0.01%	174
2015 Q4	$12.1K	Hold	56	–	–	0.02%	175
2015 Q3	$9.11K	Hold	56	–	–	0.01%	182
2015 Q2	$14.5K	Hold	56	–	–	0.02%	192
2015 Q1	$12.7K	Hold	56	–	–	0.02%	187
2014 Q4	$10.8K	Buy	+56	New	+$12K	0.01%	186

Other funds holding AXDX

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

Cypress Capital Management (Wyoming)'s AXDX Position: Q3 2019 in Review

Cypress Capital Management (Wyoming) sold out of Accelerate Diagnostics (AXDX) in Q3 2019, closing a stake of 11 shares — an estimated $3K sold.

Cypress Capital Management (Wyoming) first reported a position in AXDX in Q4 2014 and held it in 19 quarters. The position peaked at $14.5K in Q2 2015. 113 funds tracked by Wall St. Rank hold AXDX as of Q3 2019.

Cypress Capital Management (Wyoming) reported no remaining Accelerate Diagnostics position as of Q3 2019 after selling out during the quarter.
Cypress Capital Management (Wyoming) sold 11 Accelerate Diagnostics shares in Q3 2019, an estimated $3K.
Cypress Capital Management (Wyoming) first reported a position in Accelerate Diagnostics in Q4 2014 and held it in 19 quarters.
Cypress Capital Management (Wyoming)'s Accelerate Diagnostics position peaked at $14.5K in Q2 2015.
113 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q3 2019.

Based on Cypress Capital Management (Wyoming)'s 13F filing for Q3 2019, filed 12 Nov 2019.